Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment

Western and Eastern perspectives on therapeutic guidelines for hepatocellular carcinoma (HCC) have many commonalities but may also differ in certain aspects, as described in this article. In view of the limited therapeutic options for advanced HCC, evidence-based therapies are few, and thus there is a dependence on consensus-based guidelines. This article focuses on the Italian Association for the Study of the Liver guidelines and the Japanese approaches to therapy, while drawing attention to certain controversies from other academic bodies where applicable and appropriate.

[1]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .

[2]  M. Levrero,et al.  Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein , 2001, Oncogene.

[3]  R. Groszmann,et al.  American association for the study of liver diseases , 1992 .

[4]  Ding‐Shinn Chen,et al.  Percutaneous Ethanol Injection Versus Surgical Resection for the Treatment of Small Hepatocellular Carcinoma: A Prospective Study , 2005, Annals of surgery.

[5]  W. Lau,et al.  A Prospective Randomized Trial Comparing Percutaneous Local Ablative Therapy and Partial Hepatectomy for Small Hepatocellular Carcinoma , 2006, Annals of surgery.

[6]  D. Amadori,et al.  Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[8]  M. Makuuchi,et al.  Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. , 2009, Journal of hepatology.

[9]  G. Abou-Alfa Selection of patients with hepatocellular carcinoma for sorafenib. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[10]  K. Owzar,et al.  Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Pazdur,et al.  Sorafenib for the treatment of unresectable hepatocellular carcinoma. , 2009, The oncologist.

[12]  Surgery or ablation for hepatocellular carcinoma. , 2009, Annals of surgery.

[13]  G. Abou-Alfa,et al.  Advanced hepatocellular carcinoma: which staging systems best predict prognosis? , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Yong Zeng,et al.  A Randomized Trial Comparing Radiofrequency Ablation and Surgical Resection for HCC Conforming to the Milan Criteria , 2010, Annals of surgery.

[15]  D. Amadori,et al.  Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis. , 2011, Gastrointestinal cancer research : GCR.

[16]  M. Makuuchi,et al.  Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version , 2011, Digestive Diseases.

[17]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[18]  M. Kudo Treatment of Advanced Hepatocellular Carcinoma with Emphasis on Hepatic Arterial Infusion Chemotherapy and Molecular Targeted Therapy , 2012, Liver Cancer.

[19]  C. Porta,et al.  Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. , 2012, Journal of hepatology.

[20]  C. Verslype,et al.  Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  V. Mazzaferro,et al.  Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib , 2012, Clinical Cancer Research.

[22]  Riccardo Lencioni,et al.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. , 2012, Journal of hepatology.

[23]  V. Mazzaferro,et al.  EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer , 2012 .

[24]  M. Osman,et al.  Sorafenib in Advanced Hepatocellular Carcinoma-Clinical Experience , 2013 .

[25]  M. Kudo,et al.  Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Kudo,et al.  Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R. Bruno,et al.  Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. , 2013, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[28]  J. Bruix,et al.  A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis , 2013, British Journal of Cancer.

[29]  A. Gasbarrini,et al.  Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. , 2013, The Lancet. Oncology.

[30]  Osamu Matsui,et al.  Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. , 2013, Journal of hepatology.

[31]  J. Sosman,et al.  Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors , 2014, Investigational New Drugs.

[32]  L. Schwartz,et al.  Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial. , 2014, Hepatic oncology.

[33]  J. Raoul,et al.  How to Define Transarterial Chemoembolization Failure or Refractoriness: A European Perspective , 2014, Liver Cancer.

[34]  M. Kudo,et al.  Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. , 2014, JAMA.

[35]  Chih-Hung Hsu,et al.  Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy. , 2014, Journal of hepatology.

[36]  M. Kudo,et al.  GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis , 2013, International journal of clinical practice.

[37]  Y. Imai,et al.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan , 2014, Liver Cancer.

[38]  Joon-Oh Park,et al.  Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. , 2015, The Lancet. Oncology.

[39]  Joon-Oh Park,et al.  Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of patients with elevated {alpha}-fetoprotein (AFP) from the randomized phase III REACH study. , 2015 .

[40]  S. Kawasaki,et al.  Evidence‐based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH‐HCC Guidelines) , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[41]  F. Izzo,et al.  Phase III randomized study of second line ADI-peg 20 (A) plus best supportive care versus placebo (P) plus best supportive care in patients (pts) with advanced hepatocellular carcinoma (HCC). , 2016 .

[42]  C. Porta,et al.  Tumor and plasma biomarker analysis from the randomized controlled phase II trial (RCT) of tivantinib in second-line hepatocellular carcinoma (HCC). , 2016 .

[43]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.